Sign in

Quentin Blackford

President, Chief Executive Officer, Director at iRhythm Technologies
Board
Since October 2021
Age
45 years
Education
Holds dual B.S. degrees in Accounting and Business Administration from Grace College.
Tenure
Joined iRhythm Technologies, Inc. in October 2021 as President, Chief Executive Officer, and Director.

Also at iRhythm Technologies

CP
Chad Patterson
Chief Commercial Officer
DW
Daniel Wilson
Chief Financial Officer
MS
Mervin Smith
EVP of Business Operations

About

Quentin S. Blackford is a seasoned executive with extensive experience in the medical devices and healthcare technology industries, having held key leadership roles that have shaped industry practices over the past two decades. His career includes significant tenures as Chief Operating Officer at Dexcom and Chief Financial Officer at NuVasive, where he was instrumental in driving operational excellence and financial discipline.

In his earlier career, he developed a strong foundation in financial and operational management while serving at Zimmer Holdings, culminating in a role as Director of Finance and Controller of the Dental Division. These positions allowed him to sharpen his skills in strategic oversight and business transformation, preparing him for executive leadership roles later in his career.

Beyond his professional achievements, Blackford has also contributed his expertise as an independent board member for companies such as Alphatec Holdings and Paragon 28, further demonstrating his commitment to advancing innovative solutions in the healthcare sector. His background as a Certified Public Accountant (inactive) and his solid educational foundation have complemented his leadership, enabling him to make impactful decisions that drive company growth and operational improvements.

$IRTC Performance Under Quentin Blackford

Past Roles

OrganizationRoleDate RangeDetails
Dexcom, Inc. Chief Operating Officer September 2017 - September 2021 N/A
Dexcom, Inc. Chief Financial Officer September 2017 - September 2021 N/A
NuVasive, Inc. Executive Vice President, Chief Financial Officer, and Head of Strategy and Corporate Integrity February 2009 - September 2017 N/A
Zimmer Holdings, Inc. Director of Finance and Controller of the Dental Division, Leader of the Global Financial Planning and Analysis group June 1999 - September 2009 N/A

External Roles

OrganizationRoleDate Range
Paragon 28, Inc. Independent Board Member Since August 2022
Alphatec Holdings, Inc. Independent Board Member Since October 2017

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Salary$677,463AnnualFixed base salary for 2023
All Other Compensation$29,065AnnualIncludes severance & related benefits (if applicable), company-paid health plan, group term life insurance, wellness plan, and 401(k) matching up to $5,000 per year

Performance Compensation

Data from  FY 2023

Annual Bonus Plan

MetricValueDetailsCitation
Target Bonus$675,000-
Final Bonus$716,000 (106% of target)Based on actual performance metrics
Revenue Weight75%Threshold: 50%, Target: 100%, Max: 200%
Adjusted EBITDA Weight25%Threshold: 50%, Target: 100%, Max: 200%
Revenue Achieved$492.7 millionAchieved 111% payout; weighted contribution 83%
Adjusted EBITDA Achieved$(4.9) millionAchieved 70% payout; weighted contribution 18%
Individual Performance Factor105%Reflects personal leadership and achievement of strategic goals

Equity Awards - Annual RSUs & PSUs

ComponentTarget Units/AmountVesting ScheduleDetailsCitation
Annual RSUs28,775 unitsVest over 4 years; 25% vest on first anniversary (March 1, 2023) then annuallyGrant Date Fair Value: $3,460,194
Annual PSUs28,775 unitsVest over the performance period (2023-2025), certified by March 15, 2026Grant Date Fair Value: $4,022,457; subject to performance metrics including Unit Volume CAGR and Relative TSR modifiers

Equity Awards - Strategic PSUs

MetricTargetMaximumVesting ScheduleDetailsCitation
Target Units48,534 units72,801 units (150% of target)3-year cliff; vesting contingent on meeting operational goals and R-TSR performance; vesting date on August 7, 2026Grant Date Fair Value: $7,689,970; conditions include achieving 2 of 3 operational goals and R-TSR modifier (negative 25% if below 33rd percentile, positive 25% if above 75th percentile, capped at 150%)
Target Value$5,000,000$7,500,000-Units calculated based on a 20 trading-day average closing price on the grant date